Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the Stocks to Watch Right Now.

Tango Therapeutics extended its rally for a second day on Thursday to hit an all-time high, as investors took path from an investment firm’s bullish stance for its stock.

At intra-day trading, the stock climbed to its highest price of $16.97 before paring gains to finish the session just up by 36.28 percent at $16.83 apiece.

Photo by Pietro Jeng on Pexels

In a market report, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for the stock. The figure was 21 percent higher than the $12.35 closing price in the previous trading day.

This followed Tango Therapeutics Inc.’s (NASDAQ:TNGX) earnings performance last year, having narrowed its net loss by 22 percent to $101.59 million from $130.3 million in 2024. Total revenues also jumped by 48.3 percent to $62.38 million from $42.07 million year-on-year.

In the fourth quarter alone, net loss widened by 26 percent to $38.7 million from $30.76 million, as it did not earn any revenues during the period, as compared with a $5.4 million registered in the same period a year earlier.

For this year, Tango Therapeutics Inc. (NASDAQ:TNGX) is targeting to kick off a number of clinical trials to test its drug candidate vopimetostat in combination with multiple inhibitors for the treatment of pancreatic cancer.

It recently entered into a clinical trial collaboration and supply agreement with Erasca for the study of vopimetostat in combination with ERAS-0015.

.